S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.91 (+0.73%)
AAPL   265.76 (+1.19%)
FB   195.10 (+1.01%)
MSFT   149.97 (+1.29%)
GOOGL   1,333.54 (+1.86%)
AMZN   1,739.49 (-0.86%)
CGC   15.33 (-3.22%)
NVDA   204.19 (-2.67%)
MU   47.71 (+1.94%)
BABA   185.49 (+1.47%)
GE   11.52 (+2.04%)
TSLA   352.17 (+0.81%)
T   39.50 (+1.41%)
AMD   38.56 (+0.55%)
ACB   2.73 (-17.02%)
F   8.95 (+1.82%)
PRI   130.62 (+0.32%)
NFLX   295.03 (+1.87%)
BAC   32.93 (+0.70%)
GILD   65.07 (+1.97%)
DIS   144.67 (-1.69%)
Log in

Genus Share Price, Forecast & Analysis (LON:GNS)

GBX 3,076
-24.00 (-0.77 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
3,020
Now: GBX 3,076
3,106
50-Day Range
2,792
MA: GBX 2,944.51
3,146
52-Week Range
2,090
Now: GBX 3,076
3,215.60
Volume69,250 shs
Average Volume78,154 shs
Market Capitalization£2.00 billion
P/E Ratio258.49
Dividend Yield0.88%
BetaN/A
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos, which are delivered through artificial insemination to breed dairy and beef cattle with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1256-347100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£488.50 million
Cash FlowGBX 46.83 per share
Book ValueGBX 779 per share

Profitability

Miscellaneous

Employees2,900
Market Cap£2.00 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive GNS News and Ratings via Email

Sign-up to receive the latest news and ratings for GNS and its competitors with MarketBeat's FREE daily newsletter.


Genus (LON:GNS) Frequently Asked Questions

What is Genus' stock symbol?

Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS."

How often does Genus pay dividends? What is the dividend yield for Genus?

Genus announced a dividend on Thursday, September 5th. Investors of record on Thursday, November 7th will be paid a dividend of GBX 18.80 per share on Friday, November 29th. This represents a yield of 0.68%. The ex-dividend date is Thursday, November 7th. This is an increase from Genus's previous dividend of $8.90. The official announcement can be viewed at this link. View Genus' Dividend History.

What price target have analysts set for GNS?

7 Wall Street analysts have issued 1-year price objectives for Genus' shares. Their forecasts range from GBX 2,630 to GBX 3,272. On average, they expect Genus' share price to reach GBX 3,006.71 in the next twelve months. This suggests that the stock has a possible downside of 2.3%. View Analyst Price Targets for Genus.

What is the consensus analysts' recommendation for Genus?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Genus.

Has Genus been receiving favorable news coverage?

Media headlines about GNS stock have trended neutral this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Genus earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Genus.

Who are some of Genus' key competitors?

What other stocks do shareholders of Genus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco Plc Ads (BATS), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE), Experian (EXPN) and Ferguson (FERG).

Who are Genus' key executives?

Genus' management team includes the folowing people:
  • Mr. Karim Bitar, CEO & Exec. Director (Age 54)
  • Mr. Stephen Wilson, Group Fin. Director & Exec. Director (Age 59)
  • Dr. Jonathan Lightner, Chief of R&D and Scientific Officer
  • Mr. Dan Hartley, Group Gen. Counsel & Company Sec.
  • Ms. Angelle R. Rosata, Group HR Director

How do I buy shares of Genus?

Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Genus' stock price today?

One share of GNS stock can currently be purchased for approximately GBX 3,076.

How big of a company is Genus?

Genus has a market capitalization of £2.00 billion and generates £488.50 million in revenue each year. Genus employs 2,900 workers across the globe.View Additional Information About Genus.

What is Genus' official website?

The official website for Genus is http://www.genusplc.com/.

How can I contact Genus?

Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The company can be reached via phone at +44-1256-347100.


MarketBeat Community Rating for Genus (LON GNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  318 (Vote Outperform)
Underperform Votes:  270 (Vote Underperform)
Total Votes:  588
MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote "Outperform" if you believe GNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel